LTRN Stock — Lantern Pharma Inc.: Cash, EV, Pipeline

Share price

$1.55

Market cap

$19.8M

Cash

$7.4M

Enterprise value

$12.4M

Balance sheet

Cash	$7.4M
Debt	$0.0M
Net cash	$7.4M
Enterprise value	$12.4M
Basic shares	12.8M shares
Fully diluted shares	14.6M shares
Fully diluted market cap	$22.7M
Cash per share	$0.58

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading LTRN daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Oct 20, 2026	LP-184	Phase 2	Advanced Solid Tumor; Metastatic Solid Tumor; GBM	—
Jan 12 - Feb 23	LP-300	Phase 2	Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung	—
Jan 11 - Feb 22	LP-284	Phase 1	Relapsed or Refractory Lymphomas; Advanced Solid Tumor	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

LP-300

Phase 2 · Active

Aliases Tavocept

Target cysteine residues

Indications

NSCLC, never smokers, + chemotherapy (EGFR exon 21 L858R focus) (Phase 2)

Status note Phase 2 Harmonic trial in never-smoking advanced NSCLC (with chemotherapy; IND under an existing application). After a May 2026 Type C FDA meeting, future enrollment focuses on EGFR exon 21 L858R-mutant patients.

LP-184

Phase 1 · Active

Aliases STAR-001

Target DNA

Partnerships Starlight Therapeutics (wholly owned subsidiary) developing LP-184 in CNS/brain-cancer indications; company refers to the molecule as STAR-001 in CNS indications

Indications

Solid tumors (breast, bladder, lung, pancreatic) (Phase 1)
CNS cancers (glioblastoma, brain metastases, rare pediatric CNS cancers) (Phase 1)

Status note Phase 1a enrollment completed; company advancing/optimizing development plans for multiple future LP-184 clinical studies.

LP-284

Phase 1 · Active

Target DNA

Indications

Hematological cancers (Phase 1)

Status note Stereoisomer (enantiomer) of LP-184; in a Phase 1A trial, targeting hematological cancers distinct from LP-184 indications.

LP-100

Stage not disclosed · Active

Status note Company says LP-100 has potential for future development in combination with PARP inhibitors (PARPi). The 10-Q notes LP-100 (like LP-300) showed promise in patient subgroups but failed a prior pivotal Phase 3 trial on overall results; it does not state discontinuation.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	LP-300
Lead indication	Adenocarcinoma of Lung
Lead phase	Phase 2
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05456256	Phase 2	Recruiting	Sponsor	LTRN	—	Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung	—
NCT05933265	Phase 2	Active, not recruiting	Sponsor	LTRN	—	Advanced Solid Tumor; Metastatic Solid Tumor; GBM	—
NCT06132503	Phase 1	Recruiting	Sponsor	LTRN	—	Relapsed or Refractory Lymphomas; Advanced Solid Tumor	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Lantern Pharma Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

LTRN — Lantern Pharma Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials